Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna
Executive Summary
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
You may also be interested in...
Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says
COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.
Pandemic Perspectives: NCATS Director Urges Rare Disease Community To Push Against Return To Clinical Trial Status Quo
Chris Austin argued the rare disease community deserves the same “movement of heaven and earth” mentality as was employed for COVID-19.
COVID Trial Diversity: What Participants In The Vaccine Phase III Studies Look Like
Although differences in how sponsors have publicly disclosed demographic data for their enrolled trials make cross-study comparisons difficult, in general trial enrollment of Black and Hispanic participants has ranged from 10%-19% and 11%-45%, respectively, with one-quarter to one-third of study subjects falling into older age groups.